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Letters to the EditorFirst, we disagree with the exclu-
sion of studies in which the control
subjects had taken clopidogrel until 5
to 7 days before coronary artery by-
pass grafting. This excluded group is
exactly the important group that
must be assessed, because it will con-
tain many patients with recent acute
coronary syndrome, patients with
stent placement, and higher risk pa-
tients requiring ongoing clopidogrel
therapy. Because those undergoing
operation while they are receiving clo-
pidogrel are likely a similar cohort,
inclusion of patients who received
clopidogrel to that point would make
the comparison more valid.
Second, Biancari and colleagues1
predominantly used a fixed-effects
model and only used the random-
effects model when statistical hetero-
geneity was greater than a predefined
cutoff. We believe that a random-
effects model is more appropriate
when reviewing surgical cohorts,
which by their nature have significant
clinical heterogeneity. Furthermore,
nonsignificant results of tests of het-
erogeneity do not guarantee homoge-
neity between studies included in the
meta-analysis, and sources of meth-
odologic or clinical heterogeneity
should be explored.3
The more conservative nature of the
random-effects model provides more
realistic confidence intervals for
groups that can differ wildly between
surgical centers as a result of surgical
experience, the percentage of urgent
cases, and the cornucopia of different
adjunct medical therapies used.
Finally, the debate between fixed-
and random-effects models is not
new. The general consensus remains
that it is unreasonable to assume that
even with adjustment of multiple co-
variates all between-trial variation
can be accounted for, and thus the
random-effects model is preferable.4,5
From a scientific point of view,
reporting the results of both models
allows readers to judge more objec-
tively through sensitivity analysis the
robustness of the meta-analytic248 The Journal of Thoracic and Cfindings. This is particularly relevant
when the fixed-effects model for post-
operative death demonstrates a lower
95% confidence interval, just margin-
ally above the1-null effect.On reassess-
ment with a random-effects model,
we find that their effect size becomes
statistically nonsignificant, with risk
ratio of 1.28 (95% confidence interval,
0.99–1.66).
The findings regarding reduced
postoperative myocardial infarction
and increased blood product use and
reoperation remain valid.
Although the statistical change in
mortality may appear small, it re-
flects the importance of appropriate
methodologic rigor and accurate re-
porting. The original choice of model
may have been influenced by the P
value generated.
We conclude that with a change in
the statistical model from fixed to
random effects, the conclusion of
Biancari and colleages1 that observa-
tional studies show significantly
increased mortality no longer holds
true.
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On the basis of their own recent
meta-analysis on this topic,1 Nijjer
and colleagues commented on the
results of our meta-analysis about the
effects of preoperative exposure to
clopidogrel before coronary artery by-
pass grafting.2 Nijjer and colleagues
raised concerns regarding our meth-
odology, which could have affected
the results of our meta-analysis. In
our study, we used a fixed-effects
model when heterogeneity was con-
sidered unimportant. We do agree
with Nijjer and colleagues that a ran-
dom-effects model is more appropri-
ate when analyzing nonrandomized
studies. In fact, we used the latter
method in our most recent meta-
analyses. Here, we report the results
of using a random-effects model in
all outcome end points (Table 1).
The use of this method provided sim-
ilar results to those published, but ac-
cording to random-effects analysis,
the increased risk of immediate
postoperative mortality for patients
exposed to clopidogrel only tended
to be significant (risk ratio, 1.28;
95% confidence interval, 0.99–1.66;
P ¼ .06).
Nijjer and colleagues disagreed
about our decision to exclude from
the analysis those studies including
control subjects exposed to clopidog-
rel for whom the drug was discontin-
ued 5 to 7 days before surgery. Even
if Nijjer and colleagues argue that
these control subjects would include
TABLE 1. Risk of postoperative adverse events in patients who received clopidogrel versus control subjects before coronary artery bypass grafting
Outcome end points No. of studies Subjects Statistical method Effect estimate 95% CI
Immediate postoperative mortality 13 12,129 Risk ratio (M-H, random, 95% CI) 1.28 0.99–1.66
Reoperation for bleeding 14 10,944 Risk ratio (M-H, random, 95% CI) 1.78 1.28–2.48
Stroke 7 4422 Risk ratio (M-H, random, 95% CI) 1.28 0.61–2.70
Myocardial infarction 11 4084 Risk ratio (M-H, random, 95% CI) 0.64 0.49–0.83
Postoperative blood loss 10 3186 Mean difference (IV, random, 95% CI) 157.77 61.91–253.63
Red blood cell transfusion 9 10,026 Risk ratio (M-H, random, 95% CI) 1.23 1.10–1.37
Transfused red blood cells (units) 7 2369 Mean difference (IV, random, 95% CI) 0.77 0.05 to 1.59
Transfused fresh-frozen plasma (units) 7 2369 Mean difference (IV, random, 95% CI) 0.31 0.12–0.50
Transfused platelets (units) 6 741 Mean difference (IV, random, 95% CI) 2.41 0.03 to 4.86
CI, Confidence interval; M-H, Mantel-Henzel method; IV, inverse variance method.
Letters to the Editormany patients with recent acute coro-
nary syndrome and those in whom per-
cutaneous coronary interventions were
likely performed, we believe that pa-
tients for whom it was possible to dis-
continue clopidogrel 5 to 7 days before
surgery were those who were in stable
condition permitting delay of surgery
and therefore not requiring urgent or
emergency surgery. Their inclusion
would have been a potential source
of bias.
Here we take also the opportunity
to comment briefly on the differences
and similarities of these 2 meta-
analyses to get more conclusive
results on this controversial issue. In
addition to excluding studies in which
control subjects were exposed to clo-
pidogrel, we excluded from our analy-
sis those studies in which aprotinin
was used in most or all patients, be-
cause its use could have had a major
effect in reducing the risk of major
postoperative bleeding. Importantly,
we excluded studies that included pa-
tients who underwent valve surgery,
which may have significantly affected
the results of meta-analysis. The study
by Nijjer and colleagues1 did not share
these important exclusion criteria. De-
spite these methodologic differences,
our studies reached similar conclu-
sions. In fact, it seems rather clear
that recent exposure to clopidogrel be-
fore coronary surgery is associated
with increased risk of excessive bleed-
ing and need for reexploration. Fur-
thermore, in both meta-analyses we
observed a trend toward increased
mortality with recent exposure toThe Journalclopidogrel, which is consistent in
most of the included studies.
Because excessive bleeding is ama-
jor determinant of postoperative out-
come,3 we conclude that continuing
clopidogrel until the time of coronary
artery bypass grafting may expose pa-
tients to an increased risk of excessive
bleeding and its related complica-
tions. These results must be viewed,
however, in the light of suboptimal de-
sign and analysis of the included
studies.
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To the Editor:
We greatly appreciated reading the
simple but clear case report by Noda
and colleagues1 of awake thoracoscopic
surgery for intractable pneumothorax.
Noda and colleagues1 demonstrated
the benefits of local and epidural anes-
thesia in treating a particular patient
who had right pneumothorax after left
pneumonectomy for cancer. The proce-
dure was both well tolerated and suc-
cessful in completely controlling the
air leakage.
We agreewith Noda and colleagues1
that lesions situated next to the hilum
may present some difficulties in ap-
proach when operating on a breathing
lung. Nevertheless, we would first con-
tend that pulmonary tears causing air
leakage are more frequently situated
in the peripheral surface of the lung
and are therefore verywell suited to ap-
proaches performed with epidural an-
esthesia. Second, we advocate that
even hilar lesions can be reached and
treated in an awake modality after ade-
quate training.
Noda and colleagues1 also stated that
total lung collapse cannot be obtained
in patients who have limited contralat-
eral pulmonary function. In our own
awake series,2 however, lung collapse
was most of the time equivalent to
that achieved with single-lung ventila-
tion. In addition, we found that awake
video-assisted thoracoscopic manage-
ment of pneumothorax is particularly
feasible for and well tolerated by el-
derly patients and those with poorry c Volume 143, Number 1 249
